drugset / Trial / NCT04406727
UB-421 in Combination With Optimized Background Regimen in Patients With Multi-drug Resistant HIV-1 Infection
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this phase III study is to evaluate the efficacy between treatments (UB-421 Arm vs. Placebo Arm) by measuring the proportion of subjects with reduction in HIV-1 RNA viral load.
Timeline
- Start
- 2023-12-01
- Primary completion
- 2026-06-30
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SEMZUVOLIMAB | Protein / enzyme biologic | 25 mg/kg | — |